Research News

ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia

(1st May, 2014); At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine. The first poster presentation, on April 28th, found that two hours after treatment with electroCore’s nVNS therapy patients who had both chronic migraine and medication overuse headache were pain free in 33% of attacks while significant pain relief (mild or no pain) was noted in 50% of attacks. In the second poster presented on May1st it was found that 45 % of patients, with migraine without aura, were pain free within 30 minutes of just one dose of nVNS therapy.

Malignant brain tumor is new medical concern due to wi-fi and Cell Phone use

New studies escalate medical concerns about glioma (a malignant brain tumor) from cell phone use. The BioInitiative Working Group (BWG) noted that evidence for health risk from wireless technology is growing stronger and require immediate action. The Group released a mid-year update covering new science studies from 2012 to 2014.

Study shows Party drug- KETAMINE can treat severe depression

The scientists,  from Oxford Health NHS, confirmed that some patients with severe depression who have not responded to other treatments, can be treated with ketamine which has a rapid antidepressant effect. Ketamine is a licensed medical drug and is very widely used as an anaesthetic and in pain relief. It is also used as a recreational drug or drug of abuse, and is to be reclassified as a Class B banned substance.

Scientists identified genetic diversity of K.Pneumoniae (drug-resistant bacteria)

New findings, by group of scientists, will facilitate the development of new clinical strategies design to prevent or treat infections caused by multidrug-resistant Klebsiella Pneumoniae. Scientists from National Institutes of Health (NIH) and their colleagues have tracked the evolution of the Carbapenem-resistant bacterium K.pneumoniae sequence type 258 (ST258), an important agent of hospital-acquired infections by using genome sequencing.

New discovery can delay Alzheimer's development

Researchers from Michigan University have found out cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and looks like major cause of Alzeimer's Disease (AD). this mechanism helps decode amyloid plaque formation in the brains of Alzheimer's patients—plaques that kills cells and contributes to memory loss and other Alzheimer's symptoms.
The researchers discovered the molecular process behind Golgi fragmentation, and also developed two techniques to 'rescue' the Golgi structure.

Now blood test can predict Alzheimer’s and Mild Dementia

A blood test that can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease (AD) within three years has been discovered and validated by researchers at Georgetown and six other institutions. They discovered and validated 10 lipid biomarkers out of which 2 are strongly associated with neuropathology of AD.

Pages